Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study

[1] Yoshimura R(2003)Expression of peroxisome proliferator-activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists Int J Cancer 104 597-602

[2] Matsuyama M(1999)Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in human transitional bladder cancer and its role in inducing cell death Neoplasia 1 330-339

[3] Segawa Y(2005)Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial Lancet 366 1279-1289

[4] Guan YF(2009)Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive Drug Saf 32 187-202

[5] Zhang YH(2011)Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study Diabetes Care 34 916-922

[6] Breyer RM(2011)Cohort study of pioglitazone and cancer incidence in patients with diabetes Diabetes Care 34 923-929

[7] Davis L(2010)French national health insurance information system and the permanent beneficiaries sample Rev Epidemiol Sante Publique 58 286-290

[8] Breyer MD(2005)Metformin and reduced risk of cancer in diabetic patients BMJ 330 1304-1305

[9] Dormandy JA(2006)Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin Diabetes Care 29 254-258

[10] Charbonnel B(2009)The influence of glucose-lowering therapies on cancer risk in type 2 diabetes Diabetologia 52 1766-1777

[1] Yoshimura R(2003)Expression of peroxisome proliferator-activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists Int J Cancer 104 597-602

[2] Matsuyama M(1999)Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in human transitional bladder cancer and its role in inducing cell death Neoplasia 1 330-339

[3] Segawa Y(2005)Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial Lancet 366 1279-1289

[4] Guan YF(2009)Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive Drug Saf 32 187-202

[5] Zhang YH(2011)Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study Diabetes Care 34 916-922

[6] Breyer RM(2011)Cohort study of pioglitazone and cancer incidence in patients with diabetes Diabetes Care 34 923-929

[7] Davis L(2010)French national health insurance information system and the permanent beneficiaries sample Rev Epidemiol Sante Publique 58 286-290

[8] Breyer MD(2005)Metformin and reduced risk of cancer in diabetic patients BMJ 330 1304-1305

[9] Dormandy JA(2006)Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin Diabetes Care 29 254-258

[10] Charbonnel B(2009)The influence of glucose-lowering therapies on cancer risk in type 2 diabetes Diabetologia 52 1766-1777